Suppr超能文献

世界卫生组织推荐的一线通用高效抗逆转录病毒疗法(HAART)方案对印度儿童的疗效。

Efficacy of first-line, WHO recommended generic HAART regimens in Indian children.

作者信息

Parakh Ankit, Dubey A P, Kumar A, Maheshwari A, Saxena R

机构信息

Paediatric HIV Clinic, Department of Paediatrics, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India.

出版信息

Kathmandu Univ Med J (KUMJ). 2009 Jul-Sep;7(27):220-5. doi: 10.3126/kumj.v7i3.2727.

Abstract

BACKGROUND

The clinical efficacy of highly active antiretroviral therapy (HAART) in children has been well documented in the developed countries, although most of the regimens are Protease Inhibitor (PI) based which are too expensive. To circumvent this problem World Health Organization (WHO) has recommended Non- Nucleotide Reverse Transcriptase Inhibitor (NNRTI) based regimen for resource-limited countries.

AIM

To assess the long-term efficacy of first line World Health Organization (WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens in treatment -naïve children.

MATERIALS AND METHODS

Observational retrospective analysis was done. Thirty patients on HAART for >or= 6 months were included (27 on Stavudine; three on Zidovudine with Lamivudine/ Nevirapine). No protease inhibitors were used.

RESULTS

Median age was seven years (Interquartile [IQR]: 5.62-8.50) and median duration on HAART was 18 months (IQR: 6-24). No new staging events were observed after six months of initiation of HAART. The median CD4% increased from 6.0 % at baseline to 15.5% at six months, 21.7% at 12 months, 25.4% at 18 months, 24.6 % at 24 months 25.3% at 30 months and 23.7% at 36 months. There was only one case of immunological failure. Stratifi ed analysis based on baseline CD4% show that even patients with a baseline CD4 % of <5% achieved percentage of >25% at 18-24 months and maintained it subsequently. Significant increase in the weight and body mass index Z scores was observed but significant fall in the height Z scores were observed. This sub group of patients with poor linear height velocity would require detailed endocrine evaluation after testing for viral loads.

CONCLUSIONS

Non- Nucleotide Reverse Transcriptase Inhibitor based HAART regimens are feasible and effective in long term in resource-limited setting despite initiation of treatment in advanced stages. These can be continued in NACO/WHO scale up programmes at present for children.

摘要

背景

高效抗逆转录病毒疗法(HAART)在发达国家儿童中的临床疗效已有充分记录,尽管大多数治疗方案是以蛋白酶抑制剂(PI)为基础的,但其费用过于昂贵。为解决这一问题,世界卫生组织(WHO)已为资源有限的国家推荐了以非核苷类逆转录酶抑制剂(NNRTI)为基础的治疗方案。

目的

评估世界卫生组织(WHO)推荐的一线通用高效抗逆转录病毒疗法(HAART)方案在初治儿童中的长期疗效。

材料与方法

进行观察性回顾分析。纳入30例接受HAART治疗≥6个月的患者(27例接受司他夫定治疗;3例接受齐多夫定联合拉米夫定/奈韦拉平治疗)。未使用蛋白酶抑制剂。

结果

中位年龄为7岁(四分位间距[IQR]:5.62 - 8.50),HAART治疗的中位持续时间为18个月(IQR:6 - 24)。开始HAART治疗6个月后未观察到新的分期事件。CD4%中位数从基线时的6.0%增至6个月时的15.5%、12个月时的21.7%、18个月时的25.4%、24个月时的24.6%、30个月时的25.3%以及36个月时的23.7%。仅出现1例免疫失败病例。基于基线CD4%的分层分析表明,即使是基线CD4%<5%的患者在18 - 24个月时CD4%也达到>25%,并随后维持这一水平。观察到体重和体重指数Z评分显著增加,但身高Z评分显著下降。对于这一线性身高增长速度不佳的患者亚组,在检测病毒载量后需要进行详细的内分泌评估。

结论

在资源有限的环境中,尽管在疾病晚期开始治疗,但以非核苷类逆转录酶抑制剂为基础的HAART方案长期来看是可行且有效的。目前这些方案可在印度国家艾滋病控制组织(NACO)/世界卫生组织(WHO)扩大规模的儿童项目中继续使用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验